Inactive Instrument

Wintac Limited

524758

INE812C01016

Wintac Ltd. Announces Resignation of K. Paranjothy as Independent Director

August 27, 2014 at 03:03 pm IST

Wintac Ltd. announced that the Independent Director Dr. K. Paranjothy has resigned from the Board with effect from August 23, 2014 due to certain personal reasons.

Latest news about Wintac Limited

Somerset Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	10/23/10	CI
Wintac Limited Reports Earnings Results for the Full Year Ended March 31, 2022	11/22/11	CI
Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	12/20/12	CI
Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	07/20/07	CI
Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	22/20/22	CI
Wintac Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	04/20/04	CI
Wintac Limited Appoints S. Nanthitha as Additional Director	04/20/04	CI
Wintac Limited Announces Resignation of Ms. K. M. Ganga as Independent Director	27/20/27	CI
Wintac Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019	13/19/13	CI
Wintac Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	12/19/12	CI
Wintac Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	23/19/23	CI
Par Formulations Pvt Ltd cancelled the acquisition of Pharmaceutical Business from Wintac Limited.	27/19/27	CI
Wintac Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2018	11/19/11	CI
Wintac Ltd Announces Unaudited Standalone Financial Results for the Second Quarter and Six Months Ended September 30, 2018	12/18/12	CI
Wintac Ltd. Reports Unaudited Earnings Results for the First Quarter Ended June 30, 2018	07/18/07	CI
Wintac Limited Announces Resignation of B. R. Arun Eashwar as Independent Director	29/18/29	CI
Wintac Limited Announces Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2018	23/18/23	CI
Wintac Limited Appoints R.A.Thirumoorti as Additional Director	23/18/23	CI
Par Formulations Pvt Ltd agreed to acquire Pharmaceutical Business from Wintac Limited for $15.3 million.	26/18/26	CI
VEEGO PHARMA, LLC made a proposal to acquire remaining 45% stake in Wintac Limited from public shareholders for approximately INR 990 million.	23/18/23	CI
Wintac Limited Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	10/18/10	CI
Wintac Ltd Announces Unaudited Standalone Financial Results for the Second Quarter and Six Months Ended September 30, 2017	06/17/06	CI
Wintac Ltd. Reports Unaudited Earnings Results for the First Quarter Ended June 30, 2017	11/17/11	CI
Wintac Limited Announces the Resignation of Independent Directors	11/17/11	CI
Wintac Limited Appoints K. M. Ganga and K. Paranjothy as Additional Directors	27/17/27	CI

Wintac Limited is an India-based company, which is engaged in the formulations business. The Company is involved in formulation sales, manufacturing charges and formulation development. Its products are classified under categories, including injectable and ophthalmic. Its ophthalmic product range includes Timolol Maleate Eye Drops, Atropine Eye Drops, Fluorometholone Eye Drops, Olopatadine Eye Drops, Chloramphenicol Eye Drops, Diclofenac Eye Drops, Ketorolac Tromethamine Eye Drops and Bromfenac Eye Drops. Its injectable product range includes Diclofenac Injection, Pheniramine Maleate Injection, Iron Sucrose Injection, Pentoxifylline Injection, Atropine Injection, Hyoscine Butyl Bromide Injection, Ondansetron Injection, Metoclopramide Injection, Tramadol Injection, Analgin Injection, Gentamicin Sulphate Injection and Levofloxacin Injection. The Company carries out formulation development activities in the export market, including the United States, Canada, Australia and Europe.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals